8-K/A 1 awh-20210325x8ka.htm 8-K/A 2021 03-25 8KA Earnings 10K



Washington, D.C. 20549


Form 8-K/A



Pursuant to Section 13 or 15(d) of

the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 25, 2021


Aspira Women’s Health Inc.

(Exact name of registrant as specified in its charter)








(State or other jurisdiction


(IRS Employer

of incorporation)

File Number)

Identification No.)





12117 Bee Caves Road, Building III, Suite 100, Austin, Texas



(Address of principal executive offices)


(Zip Code)

Registrant’s telephone number, including area code:  (512) 519-0400


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:



Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.001 per share


The Nasdaq Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 



Explanatory Note

Aspira Women’s Health Inc. (the “Company”) is filing this Current Report on Form 8-K/A solely to correct errors in the press release issued on March 25, 2021 announcing the Company’s financial results for the three and twelve months ended December 31, 2020 (the “Original Press Release”).  The corrections related to mathematical or typographical errors in the Company’s shares outstanding and loss per share for the three months ended December 31, 2020.

Item 2.02Results of Operations and Financial Condition.

On March 25, 2021,  the Company issued the Original Press Release announcing its financial results for the three and twelve months ended December 31, 2020. A copy of the press release, as corrected, is furnished hereto as Exhibit 99.1.

The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section.  Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.

Item 9.01Financial Statements and Exhibits. 

 (d)         Exhibits



Exhibit No.





Press Release issued by Aspira Women’s Health Inc. on March 25, 2021 (as corrected)




Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.







Date: March 26, 2021


/s/ Robert Beechey


Robert Beechey


Chief Financial Officer